Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 1

AD-SVF Therapy for Refractory Endometrial Infertility

NCT07230600 · tracked via the Priya Life Science China tracker
Phase
Phase 1
Started
2025-11
Last updated
2025-11-18

Condition(s) studied

Endometrium; AtrophyIntrauterine Synechiae

Investigational drug(s) / intervention(s)

AD-SVF

AD-SVF: AD-SVF is isolated and extracted from adipose tissue for intrauterine infusion therapy.

Study summary

The purpose of this study is to initially explore the efficacy of adipose-derived stromal vascular fraction (AD-SVF) therapy in the treatment of refractory endometrial infertility.

Eligibility

Sex
FEMALE
Min age
22 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: 1. refractory thin endometrium (endometrial thickness \< 6 mm on the day of ovulation or the day of endometrial transformation during a hormone replacement cycle) and/or moderate to severe intrauterine adhesion; 2. Inability to undergo autologous bone marrow stem cells-scaffold (BMSC) transplantation due to failed bone marrow aspiration, or lack of significant effect following the BMSC treatment; 3. with fertility intentions; 4. normal ovarian function or availability of cryopreserved embryos; 5. 18kg/m\^2 \< body mass index (BMI) \< 30kg/m\^2; Exclusion Criteria: 1. Chromosomal karyotype abnormalities in one spouse; 2. Severe endometriosis, uterine fibroids affecting the uterine cavity morphology, or uterine malformations; 3. Abnormalities in coagulation function, hepatic or renal function, or other underlying conditions deemed by the investigator to potentially impact the study's progression (uncontrolled hypertension, diabetes, autoimmune diseases, etc.); 4. Contraindications for pregnancy; 5. Contraindications for hormonal cycle therapy; 6. History of pelvic tumors; 7. Simultaneous participation in other clinical studies.

Primary outcome measure(s)

  • Proportion of patients with endometrial thickness of 6 mm or greater — 6 months after AD-SVF intrauterine infusion therapy
    During the late proliferative phase, the endometrial thickness between anterior and posterior uterine walls is measured to be at least 6 mm through a median sagittal section of the uterus at least once.

Trial sites (1)

FacilityCityRegionStatus
Nanjing Drum Tower Hospital Nanjing Jiangsu Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07230600 on ClinicalTrials.gov ↗ ← All trials in China